|
 No vaccine has yet been approved to treat or prevent COVID-19, the
respiratory disease caused by the new coronavirus which has killed
more than 659,000 people and triggered economic havoc worldwide.
Financial terms of the agreement were not disclosed. Sanofi and GSK,
which had first teamed up in April, confirmed in a statement that
regulatory approval for their vaccine could be achieved by the first
half of 2021 if clinical data was to be positive.
The first clinical trials are expected in September.
The vaccine will be developed by combining Sanofi's S-protein
COVID-19 antigen and GSK's pandemic adjuvant technology.
Adjuvants are efficacy boosters that play a vital role in many
vaccines. An adjuvant is added to some vaccines to enhance the
immune response, and has been shown to create a stronger and longer
lasting immunity against infections than a vaccine alone.
[to top of second column] |
Sanofi and GSK said other discussions with the European Union, Italy and France
to supply their vaccine were ongoing.
Sanofi and GSK are hoping to clinch a deal soon to provide 300 million doses to
the European Union.
Two sources told Reuters that negotiations stalled because the company wanted to
secure an upfront payment for the entire stock while the EU would rather delay
payments until the vaccine has passed large clinical trials.
(Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
